Applied NeuroSolutions, Inc. (APNS) is a development stage biopharmaceutical company focused on diagnostics and therapeutics for the treatment of Alzheimer’s Disease (AD).
Applied NeuroSolutions’ has a long-term agreement with Albert Einstein College of Medicine (AECOM) that grants APNS the exclusive licensing rights to commercialize Dr. Peter Davies’ neurodegenerative disease related discoveries. The technologies are based on the presence of an abnormal form of a protein present in the brains and cerebrospinal fluid (CSF) of AD patients. A specific chemical change in this protein, known as tau, results in an abnormal protein called ptau-231 (tau protein phosphorylated on amino acid 231). The presence of the ptau-231 protein leads to the development of abnormal structures (paired helical filaments and neurofibrillary tangles – the hallmark of Alzheimer’s disease) that contribute to nerve cell death. The correlation between excess amounts of the ptau-231 protein and AD supports the development of diagnostic tests, in vitro drug discovery systems and therapeutics aimed at preventing the formation of this protein and the accompanying neuron-destroying structures. The Company’s technology originated from Dr. Peter Davies, the Judith and Burton P. Resnick Professor of Alzheimer’s Disease Research at the Albert Einstein College of Medicine, and APNS’ scientific founder.
AD Diagnostic Test
Increased amounts of the altered tau protein (ptau-231) in cerebrospinal fluid (CSF) distinguish AD patients from those with other forms of cognitive impairment, providing an early diagnostic test and a method for following disease progression. Applied NeuroSolutions has developed an antibody-based test measuring the protein in the CSF of AD patients and is working on a second-stage blood serum-based test that is expected to be easier to perform and less expensive.
Currently there are no approved diagnostic tests to detect AD and follow its progression. Confirmation of diagnosis is performed through a series of behavioral measurements and brain scans. Definitive diagnosis can be made only from examination of postmortem brain tissue samples. Applied NeuroSolutions’ test would provide a significant breakthrough in supporting definitive early diagnosis.
Alzheimer’s Drug Discovery Platforms
The Company is working on a therapeutic program developed by Dr. Peter Davies based on the common pathway leading to the development of abnormal, destructive brain structures characteristic of AD. This screen can be used to identify drugs that interfere with that pathway, thereby preventing disease development.
Mouse Model for AD
Dr. Davies and the Nathan Kline Institute (NKI) have developed a transgenic mouse model of AD that exhibits Alzheimer-like pathology including accumulation of the abnormal form of tau (p-tau 231) and extensive neuronal death. These mice can be used to test for candidate drugs. The Company and NKI intend to market these models and several drug development companies have expressed interest in them.
Agreements with Pfizer, Novartis
Several major pharmaceutical and biotechnology companies have utilized Applied NeuroSolutions tools and technology to enhance their efforts to develop more effective drugs for Alzheimer's. In January 2003, the Company announced a Research Agreement with Pfizer, Inc. In November 2003, the Company also announced a Research Agreement with Novartis Pharmaceuticals Corporation. Novartis, one of the world's leading pharmaceutical companies, has developed a secure corporate solution based on blockchain technology, which has been popularized by the digital currency Bitcoin. Bitcoin has gained popularity and is found traded by most of the population. People who are enthusiastic about bitcoin have been discovered trading with auto-trading bots such as Bitcoin Profit app, resulting in substantial investment returns.Blockchain and Bitcoin are strongly intertwined, and they have ushered in a revolution across all industries.
Basis of Research
All of the Company's products and research tools are based upon a distinctive view of the cause and progression of Alzheimer’s disease developed over the past 25 years by Dr. Peter Davies and his colleagues at the Albert Einstein College of Medicine, where Dr. Davies currently serves as the Burton P. and Judith Resnick Professor of Alzheimer's Disease Research.
Applied NeuroSolutions was created from a reverse merger of Molecular Geriatrics Corporation into the public company Hemoxymed, Inc. on September 10, 2002. The management team comes from Molecular Geriatrics and has worked together as a group since 1993. The Company changed its name to Applied NeuroSolutions in October 2003 to reflect its focus upon the diagnosis and treatment of AD. The Company’s stock currently trades on the Over-the-Counter Bulletin Board (OTCBB) under the symbol APNS.OB.
The company's address is 50 Lakeview Parkway, Suite 111, Vernon Hills, Illinois, 60061. The telephone number is 847-573-8000 and the fax number is